Table 1.
Baseline characteristics.
| Patient | Weight (kg), height (cm), BMI (kg/m2) | Number of comorbidities, number of cardiovascular and thrombotic risk factors | Age at ITP diagnosis (years) | Type of ITP at start of fostamatinib | Steroid exposure, IVIG, splenectomy, other previous ITP treatments | Prior unique treatments | Duration of ITP diagnosis prior to fostamatinib (years) |
|---|---|---|---|---|---|---|---|
| 1 94F Caucasian |
64, 167, 22.9 | 6 1 |
72 | Chronic | Dex and pred, no, no, azathioprine | 2 | 22.6 |
| 2 94M Caucasian |
63.4, 158, 25.4 | 11 3 |
94 | Persistent | Dex, yes, no, none | 2 | 0.2 |
| 3 80F Caucasian |
64.6, 166, 23.4 | 14 5 |
80 | Persistent | Dex and pred, yes, no, none | 2 | 0.5 |
| 4 78F Caucasian |
77, 155, 32.0 | 3 3 |
73 | Chronic | Pred, yes, no, azathioprine, TPO-RA | 4 | 5.4 |
| 5 78M Caucasian |
70, 169, 24.5 | 4 2 |
63 | Chronic | Dex and pred, yes, yes, azathioprine, rituximab, TPO-RA | 6 | 14.7 |
| 6 94F Caucasian |
65, 165, 23.9 | 6 1 |
65 | Chronic | Pred, no, no, none | 1 | 29.8 |
| 7 80M Caucasian |
82, 190, 22.7 | 2 1 |
80 | Persistent | Dex and pred, no, no, none | 1 | 0.4 |
Dex, dexamethasone; pred, prednisone; TPO-RA, thrombopoietin receptor agonist; cardiovascular and thrombotic risk factors including known thrombosis, coronary artery disease, strokes, or transient ischaemic attacks, hypertension, diabetes, dyslipidemia, and smoking.